Clinical trials: Influenza, completed
Influenza
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
This is a study for patients with flu who also have a fever as well as other flu symptoms. Patients must have had symptoms for less than 48 hours in order to participate.
- Trial name
- NCT00419263
- Testing
- Peramivir 150 mg, Peramivir 300 mg
- Where
- 69 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- BioCryst Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Influenza Human
Face Masks for Preventing Influenza Transmission
This work aims to measure the effectiveness of face mask worn by a patient with flu to avoid transmission to other persons in the household.
- Trial name
- GRIPMASK (NCT00774774)
- Testing
- control, Face mask
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza, Vaccination Coverage
Communication Intervention to Improve Influenza Vaccination Rates Among Elderly in Can Tho
This study evaluates the effectiveness of a multi-component community-based communication intervention to increase influenza vaccination rates among adults aged above 65 years in Can Tho City, Vietnam.
- Conditions
- Influenza, Vaccination Coverage, Health Communication
- Trial name
- CIVECT (NCT07508189)
- Testing
- Multi-component Health Communication Package
- Where
- Vietnam
- Volunteers
- 1,237 people, healthy volunteers welcome
- Sponsor
- Can Tho University of Medicine and Pharmacy
Influenza, Human
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Background: Vaccines are substances used to try to create resistance or immunity to a disease and to prevent an infection. Investigators are looking into improved ways to give and test the results of different kinds of vaccines.
- Trial name
- NCT00995982
- Testing
- VRC-FLUDNA056-00VP
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunization; Infection
Phase 3 Study of BK1310 in Healthy Infants
The purpose of this study is to: (cohort 1) evaluate safety and immunogenicity (Haemophilus influenzae type b, Hib) of BK1310. (cohort 2) evaluate efficacy and safety of BK1310 using ActHIB® and Tetrabik as a control in healthy…
- Trial name
- NCT02992925
- Testing
- DPT-IPV-Hib-High（Combined Vaccine）, DPT-IPV-Hib-Low（Combined Vaccine）, Hib vaccine
- Where
- 3 sites in Japan
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Immunosuppression
Influenza Vaccination in Immunocompromized Patients
Evaluation of the immunogenicity and reactogenicity of two different formulations of commercially avail-able influenza vaccines in 4 different groups of immunocompromized outpatients (HIV positive patients, patients suffering…
- Trial name
- NCT00783380
- Testing
- Virosomal influenza vaccine, Subunit influenza vaccine
- Where
- 3 sites in Switzerland
- Volunteers
- 304 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Asthma, Wheezing
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
This is a retrospective cohort study of children included in a large medical insurance claims database.
- Conditions
- Asthma, Wheezing, Immunosuppression
- Trial name
- NCT00626808
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 321,697 people
- Sponsor
- MedImmune LLC
Influenza
Trial to Describe the Safety and Immunogenicity of Fluzone®
Objective 1:To describe the safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere (NH) 2007-2008 formulation.
- Trial name
- NCT00524940
- Testing
- Inactivated, Split-Virion Influenza Virus
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with…
- Trial name
- ZX-7101A-203 (NCT05711797)
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Influenza Vaccine in Pregnant Women
In pregnant women, flu may cause complications like pneumonia (infection of the lungs) or hospitalization. In the United States (US) it is recommend that all women get flu vaccine if they are going to be pregnant or deliver…
- Trial name
- NCT00905125
- Testing
- Fluzone®, Fluarix®
- Where
- 9 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, RNA Virus Infections
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP)…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease
- Trial name
- NCT03321968
- Testing
- Quadrivalent VLP Influenza Vaccine
- Where
- 10 sites in Canada
- Volunteers
- 1,202 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza Vaccination
PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED
The goal of this research is to increase influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients).
- Trial name
- PROFLUVAXED (NCT05836818)
- Testing
- Question (Q), Messaging (M)
- Where
- 8 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Human Influenza
Bangladesh Secondary Transmission Handwashing Protocol
The next influenza pandemic is expected to spread rapidly in resource-poor settings. Influenza viruses spread from human-to-human via large respiratory droplets.
- Trial name
- NCT00880659
- Testing
- Soap
- Where
- Bangladesh
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza
Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine
The purpose of this study is to compare the immunogenicity and reactogenicity of self-administered intradermal influenza vaccine (Intanza)to nurse-administered.
- Trial name
- NCT01224613
- Testing
- Intanza
- Where
- 2 sites in Canada
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943488
- Testing
- Inactivated H1N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
The purpose of this study is to determine the immune response of three dose levels of the Quadrivalent VLP vaccine in healthy young (18-49) adults. The study is broken down into four treatment groups.
- Trial name
- NCT02307851
- Testing
- Quadrivalent VLP Vaccine, Comparator TIV
- Where
- 5 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
Primary objective: Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in…
- Trial name
- NCT00554333
- Testing
- Flu-ID 15μg, Inactivated adjuvanted Influenza Vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Allograft, Allogeneic Cell Transplantaion
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
This study is a prospective comparison between 2 popular regimens based on reduced intensity or non-myeloablative approaches to define the optimal myeloablative and/or immu-nonsuppressive association for reduced intensity…
- Conditions
- Allograft, Allogeneic Cell Transplantaion, Hematological Malignancy, Solid Tumor
- Trial name
- ITAC02-01 (NCT00894049)
- Testing
- reduced intensity conditionings
- Where
- 5 sites in France
- Volunteers
- 148 people
- Sponsor
- Institut Paoli-Calmettes
Multiple Sclerosis
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)
This will be prospective, multicentre, observational study. Patients who will initiate treatment with IFNβ-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0) i.e.
- Trial name
- INFLUENCE (NCT01706055)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Poland
- Volunteers
- 629 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.